Chris Howerton
Stock Analyst at Jefferies
(2.60)
# 2,273
Out of 4,981 analysts
70
Total ratings
45.61%
Success rate
16.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $6.61 | +21.03% | 5 | Jan 2, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $20.91 | +277.81% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.96 | +104.08% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $3.45 | +189.86% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $3.11 | +11,218.33% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $10.66 | +6,657.39% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.34 | -62.69% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $18.79 | -46.78% | 1 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $15.40 | -28.57% | 3 | Nov 30, 2022 | |
| APLS Apellis Pharmaceuticals | Downgrades: Hold | $70 → $40 | $24.85 | +60.97% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $32.39 | +88.33% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $118.42 | -24.00% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $4.51 | +166.08% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.08 | +861.54% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $24.44 | +170.10% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $4.79 | +359.29% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.76 | +1,093.18% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $1.43 | +1,438.46% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.55 | +1,388.67% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $23.61 | -11.05% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $15.91 | +3,545.51% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $1.11 | +5,305.41% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $72.87 | -78.04% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $58.82 | -54.10% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,200 | $6.29 | +18,977.90% | 1 | May 26, 2020 |
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $6.61
Upside: +21.03%
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $20.91
Upside: +277.81%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.96
Upside: +104.08%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $3.45
Upside: +189.86%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $3.11
Upside: +11,218.33%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $10.66
Upside: +6,657.39%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.34
Upside: -62.69%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $18.79
Upside: -46.78%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $15.40
Upside: -28.57%
Apellis Pharmaceuticals
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $24.85
Upside: +60.97%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $32.39
Upside: +88.33%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $118.42
Upside: -24.00%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $4.51
Upside: +166.08%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $2.08
Upside: +861.54%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $24.44
Upside: +170.10%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $4.79
Upside: +359.29%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.76
Upside: +1,093.18%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $1.43
Upside: +1,438.46%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $1.55
Upside: +1,388.67%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $23.61
Upside: -11.05%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $15.91
Upside: +3,545.51%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $1.11
Upside: +5,305.41%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $72.87
Upside: -78.04%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $58.82
Upside: -54.10%
May 26, 2020
Initiates: Buy
Price Target: $1,200
Current: $6.29
Upside: +18,977.90%